Potential Biomarkers for Diagnosis of Overactive Bladder Patients: Urinary Nerve Growth Factor, Prostaglandin E2, and Adenosine Triphosphate

키워드

참고문헌 (35)

1. Stewart WF, "Prevalence and burden of overactive bladder in the United States", World J Urol, 20, pp.327~336 (2003)
2. Lee YS, "Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study", World J Urol, 29, pp.185~190 (2011)
3. Sever N, "An investigation of lower urinary tract symptoms in women aged 40 and over", Low Urin Tract Symptoms, 9, pp.21~26 (2017)
4. Steers WD, "Depression and incontinence", World J Urol, 19, pp.351~357 (2001)
5. Liberman JN, "Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey", Urology, 57, pp.1044~1050 (2001)
6. 이학민, "Epidemiology of Lower Urinary Tract Symptoms: Emphasis on the Status in Korea", Investigative and Clinical Urology, 55(5), pp.300~308 (2014), 대한비뇨기과학회
7. Silva-Ramos M, "Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome", PLoS One, 8, pp.e64696~ (2013)
8. Steers WD, "Mechanisms of disease : the role of nerve growth factor in the pathophysiology of bladder disorders", Nat Clin Pract Urol, 3, pp.101~110 (2006)
9. Chuang YC, "The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor", J Urol, 165, pp.975~979 (2001)
10. Antunes-Lopes T, "Urinary neurotrophic factors in healthy individuals and patients with overactive bladder", J Urol, 189, pp.359~365 (2013)
11. Kuo HC, "Can urinary nerve growth factor be a biomarker for overactive bladder?", Rev Urol, 12, pp.e69~e77 (2010)
12. Liu HT, "Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection", Eur Urol, 56, pp.700~706 (2009)
13. Kim JC, "Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom", Int J Urol, 12, pp.875~880 (2005)
14. Yamauchi H, "Urinary prostaglandin E₂ was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome", Urology, 76, pp.1267.e13~1267.e19 (2010)
15. release from porcine and human normal bladder, "J Urol", 2004, 744~747
16. Cheng Y, "Correlation between cystometric volumes, ATP release, and pH in women with overactive bladder versus controls", Neurourol Urodyn, 32, pp.969~973 (2013)
17. Antunes-Lopes T, "Biomarkers in lower urinary tract symptoms", overactive bladder : a critical overview, 2014, pp.24, 352~357
18. Van Kerrebroeck P, "Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN)", Eur Urol, 64, pp.398~407 (2013)
19. Coyne KS, "Validation of the urinary sensation scale(USS)", Neurourol Urodyn, 30, pp.360~365 (2011)
20. Homma Y, "Symptom assessment tool for overactive bladder syndrome : overactive bladder symptom score", Urology, 68, pp.318~323 (2006)
21. Coyne KS, "An overactive bladder symptom and health-related quality of life short-form : validation of the OAB-q SF", Neurourol Urodyn, 34, pp.255~263 (2015)
22. Fluss R, "Estimation of the Youden Index and its associated cutoff point", Biom J, 47, pp.458~472 (2005)
23. Liu HT, "Urinary nerve growth factor level is increased in patients with interstitial cystitis", bladder pain syndrome and decreased in responders to treatment, 2009, pp.104, 1476~1481
24. Kim SW, "Urinary nerve growth factor correlates with the severity of urgency and pain", Int Urogynecol J, 25, pp.1561~1567 (2014)
25. 박경기, "Association of Urinary Urgency and Delay Time of Micturition in Women With Overactive Bladder", International Neurourology Journal, 18(3), pp.150~154 (2014), 대한배뇨장애요실금학회
26. Kim JC, "Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder", J Urol, 175, pp.1773~1776 (2006)
27. Cho KJ, "Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics", Int Urogynecol J, 24, pp.325~330 (2013)
28. Ishizuka O, "Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?", J Urol, 153, pp.2034~2038 (1995)
29. McCafferty GP, "Enhanced bladder capacity and reduced prostaglandin E2-mediated bladder hyperactivity in EP3 receptor knockout mice", Am J Physiol Renal Physiol, 295, pp.F507~F514 (2008)
30. Schüssler B., "Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. A urodynamic study", Urol Res, 18, pp.349~352 (1990)
31. Liu HT, "Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis", bladder pain syndrome and detrusor overactivity, 2010, pp.106, 1681~1685
32. Fry CH, "What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013", Neurourol Urodyn, 33, pp.602~605 (2014)
33. Sugaya K, "Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder", Biomed Res, 30, pp.287~294 (2009)
34. Cheng Y, "ATP during early bladder stretch is important for urgency in detrusor overactivity patients", Biomed Res Int, 2014, pp.204604~ (2014)
35. Vijaya G, "Reliability and validity of urinary nerve growth factor measurement in women with lower urinary tract symptoms", Neurourol Urodyn, 35, pp.944~948 (2016)

관련 논문AI추천